|
The Roadmap to Informed Healthcare
|
|
Click below to receive our
| |
|
|
Greetings! Welcome to the January issue of CrossRoads, a regular newsletter from Pharmacist Partners.
|
GlaxoSmithKline - TRANSITION STOP PAYING DOCTORS TO PROMOTE DRUGS
| |
Glaxo: Stop paying Doctors to promote DrugsWe view this recent announcement by GSK to alter the compensation metrics for their sales people as indicative of the industry-wide attempts to emphasize patient-centricity. However, this initiative seemingly flows against the prevailing information delivery and decision-making model. And GSK's actions may signal a shift of such decision-making authority from practitioners to the insurers. This undoubtedly would be an unfortunate (unintended) consequence. Ultimately success will be measured based on the magnitude of the therapeutic benefit for the patient. Notwithstanding, Pharmacist Partners, since its inception 2 years ago, continues to pioneer a contract service which enables biopharmaceutical manufacturers to augment their sales programs with consulting pharmacists - acting in an educational capacity - to improve medication literacy among patients. It is a model that enhances the incentive to ethically conduct beneficial interactions with practitioners on a peer-to-peer basis without compromising the appropriate utility of medications.
|
PanAgora SUMMIT MARCH 2014
| |
Key Topics: Identify a Holistic Multichannel Approach to Build Customer Loyalty and Trust, Patient-Centricity, Create an Dynamic Patient Experience Across All Touchpoints to Build Relationships, Physician/HCP Engagement.Pharmacist Partners own Jack Kelly, RPh and Dr. Sal Giorgianni will be participating on the panel.
|
Consultant Services - We have the ANSWERS | |
It is a pleasure to announce the launch of the Pharmacist Partners Consulting Practice. Our team, without question, compiles a valuable collection of experience and expertise which we are now making available to our clients within the health care industry. Our consulting practice is unique because our methodology begins with the perspective of the pharmacist and extends to practical applications of real-world solutions. Each area of our practice benefits from at least 20 years of experience! The accompanying flyer illustrates the depth of such expertise and the various areas of the industry that we are equipped to address - from compliance, to market research and product launch strategies.
|
January is Cervical Cancer Awareness Month
| |
Key Statistics:- In 2013, an estimated 12,340 new cases of invasive cervical cancer will have been diagnosed in U.S. women.
- In 2013, an estimated 4,030 U.S. women will have died from the disease.
- Most women with cervical cancer are diagnosed before the age of 50; from 2006-2010, the median age was 49. However, older women remain at risk. More than 20% of new cases are diagnosed in women over 65. Cervical cancer in women younger than age 20 is rare.
- In the U.S., Hispanic women have the highest rate of cervical cancer, followed by African Americans, Caucasians, American Indian/Alaska Natives, and Asian American/Pacific Islanders. Mortality rates are highest for African American women.
- When detected at its earliest stage, cervical cancer has a 5-year relative survival rate of approximately 91%. For regional disease, it is nearly 57%. If cancer has spread to distant organs, 5-year survival drops to approximately 16%. In general, the prognosis is affected by the extent of disease at the time of diagnosis.
- As of January 2010, there were approximately 250,000 cervical cancer survivors living in the U.S.
Source: EWC: Research for Health Professionals
|
|
|
Our guiding principle is in line with our clients - to improve patient health.
There is no shortage of concern for the devastating impact cervical cancer poses. Bringing added awareness to this type of cancer in January is necessary to elevating the knowledge around the disease to perhaps better diagnose, earlier in its maturation. Ultimately we are seeking a cure. While attention is focused in this regard January also brings to light potential changes within our industry. It's the start of a new year and perhaps the dawn of a new era in the biopharmaceutical market. From our perspective we are encouraged by the planned actions of an influential company such as GSK to alter certain business practices. However this sense of a shift in the industry is also met with a degree of tempered optimism. GSK can certainly lead the charge but other companies must follow in order for patients to realize the benefits. After all, the intention is to move from a product-focused industry to a patient-centric or patient-driven one. At the same time we want to ensure all practitioners are fully informed to interact with patients in a meaningful way so the patient feels empowered. Pharmacist Partners, like GSK, is a pioneer in this sense. Our model is predicated on the quality of the interaction our pharmacists have with practitioners. Their incentive is to create trust among their peers and improved adherence for our clients medication. Happy New Year!
Sincerely,
David
David Perry, CEO Pharmacist Partners LLC 855-742-7611
|
|
|
|
|